A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis

References

Page 1

	Year	Citations
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use A.Y. Finlay, Ghazala Khan Clinical and Experimental Dermatology Quality Of LifeLife AssessmentAllergyDermatology PatientsAtopic Dermatitis	1994	5.4K
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair, New England Journal of Medicine	2000	3K
Severe Psoriasis – Oral Therapy with a New Retinoid T Fredriksson, U. Pettersson Dermatology	1978	2.7K
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld, The Lancet InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryAutoimmune Disease	1999	2.3K
Psoriasis causes as much disability as other major medical diseases Stephen R. Rapp, Steven R. Feldman, M. Lyn Exum, Journal of the American Academy of Dermatology Autoimmune DiseaseDisease MechanismMedicineClinical DermatologyMuch Disability	1999	1.5K
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS P Eter E. L Ipsky, E. W Illiam, D Aniel E. F Urst, InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryAutoimmune Disease	2000	1.2K
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Kristian Reich, Frank O. Nestlé, Kim Papp, The Lancet Infliximab InductionSystemic TreatmentPhase IiiClinical TrialsPsoriatic Arthritis	2005	1K
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial Umesh Chaudhari, Pat Romano, LD Mulcahy, The Lancet InflammationPlaque-type PsoriasisInfliximab MonotherapyMedicineRandomised Trial	2001	903
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin, Arthritis & Rheumatism	2005	899
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Christian Antoni, Gerald G. Krueger, Kurt de Vlam, Annals of the Rheumatic Diseases	2005	704

Page 1